-
effectivehealthcare-admin.ahrq.gov/products/breast-abnormalities-tests-update/research
December 01, 2019 - We used the summary likelihood ratios and Bayes' theorem to calculate the post-test probability of having
-
effectivehealthcare-admin.ahrq.gov/products/predictors-trauma-care/research-2018
December 01, 2019 - We used data provided to calculate values that were not reported and pooled estimates across studies
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/meditation_research-protocol.pdf
October 17, 2012 - For studies amenable to pooling with meta-analyses, we will calculate pooled mean differences, risk … When we are unable to pool studies, we will calculate and display the individual mean differences, risk … Since many trials do not provide enough
information to calculate a confidence interval
around the difference … For studies amenable to pooling with
meta-analyses, we will calculate
pooled mean differences, risk … When we are unable to pool studies,
we will calculate and display the
individual mean differences,
-
effectivehealthcare-admin.ahrq.gov/products/gestational-diabetes-screening-diagnosis/research-protocol
December 01, 2019 - If necessary, we will approximate means by medians and use 95% confidence intervals to calculate approximate … We will calculate p-values when they are not reported. 26
For KQ1, we will construct 2x2 tables and … calculate sensitivity, specificity, positive and negative predictive values, reliability and yield of … For continuous variables, we will calculate mean differences for individual studies.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_executive.pdf
September 01, 2009 - difference
Insufficient Data are inadequate to calculate outcomes or are not reported.
5
Key Question … difference
Insufficient Data are inadequate to calculate outcomes or are not reported.
7
Key Question
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/gestational-diabetes-screening-diagnosis_research-protocol.pdf
December 16, 2011 - If necessary, we will approximate means by medians and use 95%
confidence intervals to calculate approximate … We will calculate p-values
when they are not reported.
26
For KQ1, we will construct 2x2 tables … and calculate sensitivity, specificity, positive and
negative predictive values, reliability and yield … For continuous variables, we will calculate mean differences for individual studies.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/glaucoma-screening_research-protocol.pdf
November 16, 2010 - Measures of treatment effect
We will calculate summary risk ratios or odds ratios as appropriate for … For Key
Question 3, we will calculate diagnostic odds ratios. … We will verify normality of continuous outcomes
and calculate mean differences; standardized mean differences
-
effectivehealthcare-admin.ahrq.gov/products/glaucoma-screening/research-protocol
December 01, 2019 - Measures of treatment effect
We will calculate summary risk ratios or odds ratios as appropriate for … For Key Question 3, we will calculate diagnostic odds ratios. … We will verify normality of continuous outcomes and calculate mean differences; standardized mean differences
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/trauma-child-interventions_disposition-comments.pdf
February 11, 2013 - We did not use any data from unreported
studies (e.g., Kramer and Landolt, 2011) to
calculate our effect
-
effectivehealthcare-admin.ahrq.gov/products/cardiology-health-outcomes/research
January 01, 2019 - We used Kaplan-Meier methods to calculate unadjusted 30-day and 1-year mortality rates.
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/c-difficile-update_research-protocol.pdf
December 23, 2014 - available, we will use statistical differences to
assess efficacy and comparative effectiveness and calculate … Since two primary endpoints
will be used, sensitivity and specificity, we will calculate 99 percent … Depending on the heterogeneity of prevalence of CDI in diagnostic accuracy
studies, we may also calculate … Further, when possible, we will calculate positive and negative
likelihood ratios that allow clinicians … We will calculate risk ratios (RR)
and absolute risk differences (RD) with the corresponding 95 percent
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/preterm-birth-terbutaline-pump_research-protocol.pdf
October 18, 2010 - As appropriate for each outcome outlined in KQ1 through KQ4, we will calculate
the following summary … confidence intervals:
• For continuous outcomes (e.g., gestational age at delivery, birthweight) we will
calculate … neonatal brochopulmonary dysplasia,
retinopathy of prematurity, maternal pulmonary edema) we will calculate … • For the time to event outcome (i.e. time to delivery) we will calculate the
pooled hazard ratio … , dislodgement and overdoses) we will
pool reported incidence data using a random effects model to calculate
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/johnson_-ahrq-mcda-presentation.pdf
August 27, 2012 - Slide 1
Research Triangle Institute
RTI International is a trade name of Research Triangle Institute. www.rti.org
The Use of Conjoint Analysis to Elicit
Patient Preferences in Selecting
Treatment Endpoints
F. Reed Johnson, PhD
Distinguished Fellow and Principal Economist
Research Triangle Institute
I…
-
effectivehealthcare-admin.ahrq.gov/products/quantitative-synthesis-expanded-methods/methods
December 01, 2019 - Similar to relative risk, investigators should calculate NNT/NNH based on combined hazard ratio or rate … For time to event data and count data, investigators should also calculate NNT/NNH while incorporating
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/stakeholders-engagement-others_research-2011.pdf
January 01, 2011 - Engaging Stakeholders to Identify and Prioritize Topics for Future Research: Recommended activities and reporting practices
1
Engaging Stakeholders to Identify and Prioritize Topics for Future Research: Recommended
activities and reporting practices
This table presents a series of recommended activities for resea…
-
effectivehealthcare-admin.ahrq.gov/products/migraine-prevention/research-protocol
December 01, 2019 - For categorical variables we will abstract the number of events among treatment groups to calculate rates … Means and standard deviations of continuous variables will be abstracted to calculate mean differences … analysis set, we will abstract the number randomized to each treatment group as the denominator to calculate … Using Meta-Analyst 52 and STATA® 53 software at a 95 percent CI, we will calculate the relative risk … risk differences (ARD) in rates of outcome events in the active and control groups. 53, 59 We will calculate
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/urinary-incontinence-treatment_research-protocol.pdf
September 30, 2010 - For categorical variables we
will abstract a number of events among treatment groups to calculate rates … Means and standard deviations of continuous variables will be
abstracted to calculate mean differences … trials (RCTs), we will abstract the number randomized to each
treatment group as the denominator to calculate … We will calculate relative risk and absolute risk difference from the abstracted events using
Meta-analyst91 … We may calculate standard
deviations when authors report standard errors:
Standard deviation
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/hypertension-drugs-utilization_research.pdf
January 25, 2011 - Payments for
Antihypertensive Drugs: For each of
the study years of interest, we used Part
D claims to calculate
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/data-points_1_diabetic-foot-ulcers_data_02-2011.xlsx
January 01, 2011 - Prevalence of Diabetes
Prevalence of Diabetes in Medicare Parts A and B Fee-for-Service (FFS) Cohort Population (Millions), 2007
Algorithm Period of continuous enrollment (months) Number of Beneficiaries in Enrollment Population Number of Beneficiaries with Diabetes Diabetes Rate in Enrolled Population
1 1 34.6 9…
-
effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/colorectal-cancer-staging_executive.pdf
September 01, 2014 - 1
Comparative Effectiveness Review
Number 142
Imaging Tests for the Staging of Colorectal
Cancer
Executive Summary
Background
Colorectal Cancer
In the United States each year colon cancer
is diagnosed in approximately 100,000
people and rectal cancer is diagnosed in
another 50,000.1 Colorectal cancer usually…